Thyroid dysfunction in patients with childhood-onset medulloblastoma or primitive neuroectodermal tumor

Area of Science:

• Pediatric Oncology
• Endocrinology
• Radiation Oncology

Background:

• Medulloblastoma and primitive neuroectodermal tumors (PNET) are common pediatric brain cancers.
• Treatment often involves radiotherapy and chemotherapy, which can lead to long-term side effects.
• Thyroid dysfunction is a known complication of these treatments.

Purpose of the Study:

• To investigate the clinical characteristics of thyroid dysfunction in pediatric patients with medulloblastoma or PNET.
• To identify risk factors for hypothyroidism following radiotherapy and chemotherapy in this patient population.

Main Methods:

• Retrospective review of 66 pediatric patients treated for medulloblastoma or PNET.
• Analysis of patients who received high-dose chemotherapy with autologous stem cell rescue (HDCT/ASCR).
• Statistical analysis using log-rank test and Cox proportional hazard model to identify predictors of hypothyroidism.

Main Results:

• 74% of patients developed hypothyroidism (transient or permanent) during a median follow-up of 7.6 years.
• Younger age (<5 years) at radiation exposure and HDCT were significant predictors of hypothyroidism.
• Tumor type, sex, and radiation dose were not significant predictors.

Conclusions:

• Thyroid dysfunction is highly prevalent in pediatric medulloblastoma/PNET survivors.
• Early age at radiation exposure and HDCT are key risk factors for developing hypothyroidism.
• Mandatory and frequent thyroid function monitoring is crucial for all treated patients, especially the very young and those undergoing HDCT/ASCR.